▼ -5.67% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $266.43, with a high forecast of $300.00 and a low forecast of $230.00. The average price target represents a -5.67% upside from the last price of $282.45.
The current consensus among 15 contributing investment analysts is to hold stock in Insulet. This rating has held steady since March 2020, when it changed from a Buy consensus rating.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.